Haleon Pakistan starts local manufacturing of Panadol 500mg tablets

Haleon Pakistan Limited HALEON said it commenced manufacturing Panadol 500mg tablets at its own facility in Jamshoro, Pakistan, according to a filing with the Pakistan Stock Exchange dated 30 October 2026.

The company said the start of in-house production follows its previously announced investment on 13 October 2023 in the Jamshoro facility to produce the Panadol base portfolio. The investment was undertaken to bring the latest manufacturing technology to Pakistan and enhance production capacity.

Panadol 500mg tablets made at Jamshoro will feature a beacon engraving in place of the existing “Panadol” text engraving. Haleon Pakistan said the change is limited to the tablet design and that product quality and efficacy remain unchanged.

The company said the commencement of manufacturing strengthens its in-house manufacturing capabilities and bolsters the reliable availability of its products for consumers in Pakistan. Haleon Pakistan closed at Rs 661.25 on Thursday.